Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 1;10(11):2452.
doi: 10.3390/jcm10112452.

Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic

Shiva Rattan Ambardar  1 , Stephanie L Hightower  1   2 , Nikhil A Huprikar  1   2 , Kevin K Chung  1   2 , Anju Singhal  3 , Jacob F Collen  1   2
Affiliations
Review

Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic

Shiva Rattan Ambardar et al. J Clin Med. .

Abstract

Since the initial identification of the novel coronavirus SARS-CoV-2 in December 2019, the COVID-19 pandemic has become a leading cause of morbidity and mortality worldwide. As effective vaccines and treatments begin to emerge, it will become increasingly important to identify and proactively manage the long-term respiratory complications of severe disease. The patterns of imaging abnormalities coupled with data from prior coronavirus outbreaks suggest that patients with severe COVID-19 pneumonia are likely at an increased risk of progression to interstitial lung disease (ILD) and chronic pulmonary vascular disease. In this paper, we briefly review the definition, classification, and underlying pathophysiology of interstitial lung disease (ILD). We then review the current literature on the proposed mechanisms of lung injury in severe COVID-19 infection, and outline potential viral- and immune-mediated processes implicated in the development of post-COVID-19 pulmonary fibrosis (PCPF). Finally, we address patient-specific and iatrogenic risk factors that could lead to PCPF and discuss strategies for reducing risk of pulmonary complications/sequelae.

Keywords: ARDS; COVID-19; SARS-CoV-2; coronavirus; interstitial lung disease; mechanical ventilation; pneumonia; pulmonary fibrosis; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Injury → Inflammatory response → Repair → Fibrosis.
See this image and copyright information in PMC

References

    1. Polak S.B., Van Gool I.C., Cohen D., von der Thüsen J.H., van Paassen J. A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol. 2020;33:2128–2138. doi: 10.1038/s41379-020-0603-3. - DOI - PMC - PubMed
    1. George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 2020;8:807–815. doi: 10.1016/S2213-2600(20)30225-3. - DOI - PMC - PubMed
    1. Kalchiem-Dekel O., Galvin J.R., Burke A.P., Atamas S.P., Todd N.W. Interstitial lung disease and pulmonary fibrosis: A practical approach for general medicine physicians with focus on the medical history. J. Clin. Med. 2018;7:476. doi: 10.3390/jcm7120476. - DOI - PMC - PubMed
    1. Lechowicz K., Drozdzal S., Machaj F., Rosik J., Szostak B., Zegan-Baranska M., Biernawska J., Dabrowski W., Rotter I., Kotfis K. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J. Clin. Med. 2020;9:1917. doi: 10.3390/jcm9061917. - DOI - PMC - PubMed
    1. Ueno M., Maeno T., Nomura M., Aoyagi-Ikeda K., Matsui H., Hara K., Tanaka T., Iso T., Suga T., Kurabayashi M. Hypoxia-inducible factor-1α mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011;300:L740–L752. doi: 10.1152/ajplung.00146.2010. - DOI - PubMed